Cerenome, Inc.

AI-generated fair value estimate for this company.

Method: Net asset (cash) floor: $8.6M total cash & short-term investments (6/30/26, debt ~$0 after mid-2026 payoff of the $750K line of credit) divided by 7.59M shares outstanding (Oct 2026).

Reasoning: Cerenome (formerly Plus Therapeutics) has only a single nascent commercial product (CNSide, ~$0 material revenue yet) and a burn rate ($6.7M/quarter) that exceeds its cash cushion, so near-term going-concern/dilution risk dominates; a cash-based floor is more grounded than forecasting unproven commercial ramp cash flows.